机构：[1]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[2]Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing University, Chongqing, China
Head and neck squamous cell carcinoma (HNSCC) remains one of the most
challenging solid tumors to manage, with persistently suboptimal survival outcomes
despite advancements in surgery, radiotherapy, and chemotherapy (1). Over the past
decade, immune checkpoint inhibitors (ICIs)—particularly those targeting programmed
cell death protein 1 (PD-1) and its ligand PD-L1—have revolutionized the treatment
landscape of multiple malignancies, including HNSCC (2, 3). By reinvigorating cytotoxic
T-cell responses, ICIs have demonstrated durable clinical benefits in subsets of patients
with recurrent and metastatic disease, and in some contexts, have even redefined standards
of care. Nevertheless, the response rates to ICIs in HNSCC remain limited to a fraction of
patients, and the complexity of immune resistance, tumor heterogeneity, and adverse
immune-related events pose significant barriers to universal efficacy (4, 5).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|2 区医学
小类|2 区免疫学
最新[2025]版：
大类|2 区医学
小类|2 区免疫学
第一作者：
第一作者机构：[1]Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
通讯作者：
推荐引用方式(GB/T 7714)：
Liu Zheran,Cai Lei,Peng Xingchen.Editorial: Opportunities and challenges of head and neck cancer treatment in the era of immune checkpoint inhibitors[J].Frontiers In Immunology.2025,16:1656915.doi:10.3389/fimmu.2025.1656915.
APA：
Liu Zheran,Cai Lei&Peng Xingchen.(2025).Editorial: Opportunities and challenges of head and neck cancer treatment in the era of immune checkpoint inhibitors.Frontiers In Immunology,16,
MLA：
Liu Zheran,et al."Editorial: Opportunities and challenges of head and neck cancer treatment in the era of immune checkpoint inhibitors".Frontiers In Immunology 16.(2025):1656915
